Lei Jianping reported on October 2
Wuhan Xinhuayang Biological Co., Ltd. (abbreviated as "New Huayang Biology") Listed on the Science and Technology Innovation Board.
Xinhua Yang plans to raise 530 million yuan this time, of which 245 million yuan will be used for the refining project of biological enzyme preparations, and 157 million yuan will be used for feed enzyme preparations and microecological fermentation bases Expansion project (Phase I), 130 million yuan will be used for the construction of the Xinhuayang Biotechnology R&D and Innovation Platform.
's annual revenue is nearly 400 million
Xinhua Yang Biotechnology is applying modern biotechnology to develop, produce and sell products such as enzyme preparations and microecological products to customers. A biotechnology company that provides "safe, efficient, and environmentally friendly" system solutions.
enzyme is produced by living cells that can catalyze specific substrate proteins, RNA or its complexes, which can efficiently catalyze various biochemical reactions at room temperature and pressure , To promote the metabolism of organisms, so it is called "biocatalyst".
Enzyme preparation is a biological product with catalytic function formed after the separation and purification of enzymes by biotechnology. It can be widely used in medicine, food, and bioenergy. Washing, agriculture and animal husbandry, textiles, environmental protection, papermaking and general health and other fields.
microecological preparations, beneficial microorganisms isolated from animals or nature, biological preparations containing live bacteria or bacterial cells and their products made by special processes such as culture, fermentation, drying, etc., can be widely used In the fields of medicine, food, bio-energy, agriculture and animal husbandry, environmental protection and general health.
prospectus shows that Xinhuayang Biotech's revenue in 2018, 2019, and 2020 will be 339 million yuan, 326 million yuan, and 395 million yuan, respectively; Xinhuayang Biotechnology's revenue in the first quarter of 2021 will be 118 million yuan Yuan.
The net profit of Xinhuayang Biotech in 2018, 2019 and 2020 will be 55.28 million yuan, 67.91 million yuan, and 95.89 million yuan; Xinhuayang Biotechnology's net profit for the first quarter of 2021 will be 33.56 million yuan .
Zhan Zhichun and his daughter are the actual controllers
The actual controller of Xinhua Yang Biological Company Zhan Zhiquan, ZHI 56% of the total voting control.
Before the IPO, Zhan Zhichun directly held 20,666,700 shares of the company, accounting for 37.58% of the company’s total voting shares, and served as the chairman of the company.
Xinhuayang Investment, Wuhan Huaixin, Wuhan Muying, and Wuhan Junmao controlled by Zhan Zhichun hold 2.25 million shares, 3 million shares, 1 million shares, and 1 million shares of the company, respectively, accounting for the company’s voting shares The total proportions were 4.09%, 5.45%, 1.82%, 1.82%. Zhan Zhichun controls 50.76% of voting rights in total.
ZHANYIYANG is the daughter of Zhan Zhichun, who indirectly holds 0.82% of the company's shares through Xinhuayang Investment and serves as a director of the company.
Zhan Zhichun, born in February 1964, East China University of Science and Technology Bachelor of Biochemistry. From August 1987 to December 1995, he served as an engineer of the National Feed Testing Center (Wuhan); in 1995, he established Wuhan Huayang Biological Nutrition Engineering Co., Ltd.; in 2000, he established Xinhuayang Co., Ltd. and served as the chairman of the company.
ZHANYIYANG, born in December 1991, Canadian nationality, graduated from McGill University in Canada in 2015 with a major in biochemistry. In 2019, he obtained a Master of Business Administration (MBA) degree from the Said Business School of Oxford University (Oxford). Ms. ZHANYIYANG once worked in Jiangxi Xinhuayang Enzyme Technology Co., Ltd., and is currently a director, assistant to the chairman and director of the international business department of the company.
After the IPO, Zhan Zhichun holds 28.18%, Gaonong Group (SS) holds 7.95%, Yu Shuanna holds 5.45%, and Shenzhen Health & Health holds 5.11% , Suzhou Houqi holds 5.01% of the shares.
———————————————
Lei Di was founded by senior media person Lei Jianping. If reprinted, please indicate the source.
.
